---
title: Frontline Treatment of Mantle Cell Lymphoma
date: '2024-03-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38498174/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240319180519&v=2.18.0.post9+e462414
source: Blood
description: Despite many recent therapeutic advances, mantle cell lymphoma (MCL)
  remains a largely incurable disease. Treatments for patients with relapsed/refractory
  (R/R) disease are limited in number and in response durability. Therefore, improving
  the efficacy of frontline (1L) treatment, and specifically maximizing the duration
  of first remission, remains of critical importance to obtain favorable long-term
  outcomes. As 1L treatments become more effective, improving tolerability is also
  becoming ...
disable_comments: true
---
Despite many recent therapeutic advances, mantle cell lymphoma (MCL) remains a largely incurable disease. Treatments for patients with relapsed/refractory (R/R) disease are limited in number and in response durability. Therefore, improving the efficacy of frontline (1L) treatment, and specifically maximizing the duration of first remission, remains of critical importance to obtain favorable long-term outcomes. As 1L treatments become more effective, improving tolerability is also becoming ...